Search results
Results from the WOW.Com Content Network
Gartner was the target of a federal lawsuit (filed May 29, 2009) from software vendor ZL Technologies challenging the "legitimacy" of Gartner's Magic Quadrant rating system. [7] Gartner filed a motion to dismiss by claiming First Amendment protection since it contends that its MQ reports contain "pure opinion", which legally means opinions that ...
CEB, formerly Corporate Executive Board, now a part of Gartner, was a company providing best practice research, benchmarks, and decision support tools to business leaders in HR, Finance, IT, Marketing, Sales, Customer Service, Strategy, R&D, Procurement, Legal, and Compliance functions globally. [3]
Printable version; In other projects Wikidata item; ... This is a list of major breast cancer cell lines that are primarily used in breast cancer research. [Notes 1]
Diagnosis dates are listed where the information is known. Breast cancer is the second most common cancer in women after skin cancer. According to the United States National Cancer Institute, the rate of new cases of female breast cancer was 129.1 per 100,000 women per year. The death rate was 19.9 per 100,000 women per year.
Since the Breast Cancer Research Stamp was first offered for sale in 1998 the DOD BCRP has received 30% from the sales of the US Postal Service's first class Breast Cancer Research Stamp (Public Law 105–41, Stamp Out Breast Cancer Act [H.R. 1585]), totalling $16,387,657.27.
(Reuters) -Moderna shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in ...
Cost-plus pricing is a pricing strategy by which the selling price of a product is determined by adding a specific fixed percentage (a "markup") to the product's unit cost. Essentially, the markup percentage is a method of generating a particular desired rate of return. [1] [2] An alternative pricing method is value-based pricing. [3]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.